University of New Mexico Cancer Center Support

新墨西哥大学癌症中心服务于广阔的美丽地理区域，拥有丰富的多元文化和多民族多样性，巨大的科学机会，以及挑战健康和社会经济差距，新墨西哥大学癌症中心及其联盟机构-洛夫莱斯呼吸研究所，洛斯阿拉莫斯国家实验室和桑迪亚国家实验室-在癌症研究方面取得重大进展，为我们的社区和国家服务。作为500英里半径内唯一的NCI癌症中心，新墨西哥大学癌症中心的特点包括：它所服务的多种族和多元文化人群——主要是西班牙裔/拉丁裔、美洲印第安人和非西班牙裔白人——他们的癌症发病率、死亡率和差异模式截然不同；将工程、生物技术、纳米技术、放射性同位素、药物发现、成像和高性能计算等区域科学优势整合到其研究项目和共享资源中；以及它为提供癌症治疗、文化适宜的社区教育和参与性研究以及社区肿瘤学家参与新墨西哥大学癌症中心临床试验而建立的广泛的全州外展网络。自2005年上次NCI P30 CCSG审查以来，该中心每年的同行评审研究经费增加了40%，达到4680多万美元，而NCI的年度资助增加了30%，达到1380多万美元。中心117个成员之间的方案内和方案间合作

Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the University of New Mexico Cancer Center and its consortium institutions - Lovelace Respiratory Research Institute, Los Alamos National Laboratory, and Sandia National Laboratories - are uniquely poised to make significant advances in cancer research and to serve our communities and our nation. As the only NCI Cancer Center within a 500 mile radius, the special characteristics of the UNM Cancer Center include: the multiethnic and multicultural populations that it serves - primarily Hispanic/Latino, American Indian, and non-Hispanic White - with their strikingly different patterns of cancer incidence, mortality, and disparity; the integration of regional scientific strengths in engineering, biotechnology, nanotechnology, radioisotopes, drug discovery, imaging, and high performance computing into its Research Programs and Shared Resources; and the extensive statewide outreach networks it has built for the delivery of cancer care, for culturally appropriate community-based education and participatory research, and for the participation of community oncologists in UNM Cancer Center clinical trials. Since the previous NCI P30 CCSG review in 2005, the Center's annual peer-reviewed research funding has increased 40% to over $46.8 million dollars in total costs, while annual funding from NCI increased 30% to over $13.8 million dollars. Intra-programmatic and inter-programmatic collaborations among the 117 members of the Center have increased markedly and range from 20-48% in each of the 4 Research Programs: Cancer Population Sciences, Cancer Biology and Biotechnology, Hematologic Malignancies, and Women's Cancers. Cancer Center members lead one of 9 NIH-funded Roadmap Centers for High Throughput Target Screening and Molecular Discovery {U54MH084690), one of 10 NIH-funded National Centers for Systems Biology (P50GM085273), one of 4 NSF/NCI Centers for Integrative Nanoscience and Microsystems Training (DGE0504276), one of 20 LLS Specialized Centers of Leukemia Research (LLS SCOR 7388-06), and an Interdisciplinary HPV Prevention Center (NIH U19AI084081). To assure that all New Mexicans have access to outstanding cancer diagnosis and treatment, the UNM Cancer Center opened its new 206,432 sq. ft., $90 million, Cancer Treatment and Clinical Research Facility in August 2009 which serves as the hub of the UNM Statewide Cancer Care Network. In collaboration with Siemens, this new facility contains a radioisotope production laboratory and experimental radiopharmacy, which will accelerate the Center's research programs. From 7/1/08-7/1/09, while maintaining its mission to the underserved and uninsured, the UNM Cancer Center ccrued 443 (17%) of the 2640 newly diagnosed patients treated at the Center to therapeutic clinical trials; 51% of these patients were Hispanic or American Indian. Community affiliates accrued another 101 patients to UNM therapeutic trials. In addition, the Center had 845 accruals to non-intervention protocols in this time period. The overall goals of the UNM Cancer Center are to: 1) conduct outstanding transdisciplinary research in our laboratories, clinics and multiethnic and multicultural communities that builds upon our unique scientific and regional strengths; 2) reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and cancer disparities in the peoples of the American Southwest; 3) translate our scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials; and 4) provide access to outstanding cancer treatment and clinical trials for all New Mexicans.